Literature DB >> 12542525

Familial and attributable risks in cutaneous melanoma: effects of proband and age.

Kari Hemminki1, Hong Zhang, Kamila Czene.   

Abstract

We studied familial risks in invasive and in situ cutaneous melanoma by comparing the occurrence of melanoma, or discordant cancer, between parents and offspring, and between siblings, based on the Swedish Family Cancer Database of over 10 million individuals. Offspring were 0-66 y of age. Cancers were obtained from the Swedish Cancer Registry from 1961 to 1998. The study was based on 24,818 invasive and 5510 in situ cases of melanoma. Standardized incidence ratios were calculated for familial risk. The standardized incidence ratios for offspring was 2.40 (95% confidence intervals: 2.10-2.72) when only the parent had melanoma and it was 2.98 (95% confidence intervals: 2.54-3.47) when only a sibling was affected; when both a parent and a sibling were affected the standardized incidence ratios was 8.92 (95% confidence intervals: 4.25-15.31). The respective population attributable risks were 1.38, 1.20, and 0.10%. The familial risk showed a clear age dependence and somewhat higher risk in in situ melanoma than in the invasive counterpart. The highest standardized incidence ratio of 61.78 (5.82-227.19) was noted for offspring whose parent had multiple melanomas. Superficially spreading melanoma showed the highest familial risk both among invasive and in situ tumors. Melanoma associated with breast, nervous system, and skin cancers, and in situ melanoma possibly also with connective tissue and thyroid tumors and multiple myeloma.

Entities:  

Mesh:

Year:  2003        PMID: 12542525     DOI: 10.1046/j.1523-1747.2003.12041.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  16 in total

1.  A hierarchical frailty model applied to two-generation melanoma data.

Authors:  Tron Anders Moger; Marion Haugen; Benjamin H K Yip; Håkon K Gjessing; Ornulf Borgan
Journal:  Lifetime Data Anal       Date:  2010-11-04       Impact factor: 1.588

2.  Blood DNA methylation, nevi number, and the risk of melanoma.

Authors:  Laura Pergoli; Chiara Favero; Ruth M Pfeiffer; Letizia Tarantini; Donato Calista; Tommaso Cavalleri; Laura Angelici; Dario Consonni; Pier A Bertazzi; Angela C Pesatori; Maria T Landi; Valentina Bollati
Journal:  Melanoma Res       Date:  2014-10       Impact factor: 3.599

Review 3.  Conceptual approach to early melanoma detection: models, tools, issues and challenges.

Authors:  Shadi Damanpour; James M Grichnik
Journal:  Melanoma Manag       Date:  2015-11-24

Review 4.  State of melanoma: an historic overview of a field in transition.

Authors:  Vikram C Gorantla; John M Kirkwood
Journal:  Hematol Oncol Clin North Am       Date:  2014-06       Impact factor: 3.722

5.  High accuracy of family history of melanoma in Danish melanoma cases.

Authors:  Karin A W Wadt; Krzysztof T Drzewiecki; Anne-Marie Gerdes
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

Review 6.  Genetic and environmental melanoma models in fish.

Authors:  E Elizabeth Patton; David L Mitchell; Rodney S Nairn
Journal:  Pigment Cell Melanoma Res       Date:  2010-03-08       Impact factor: 4.693

Review 7.  Genetic risk factors for melanoma.

Authors:  Kathrine Damm Meyle; Per Guldberg
Journal:  Hum Genet       Date:  2009-07-08       Impact factor: 4.132

8.  The geographic distribution of melanoma incidence in Massachusetts, adjusted for covariates.

Authors:  Laurie M DeChello; T Joseph Sheehan
Journal:  Int J Health Geogr       Date:  2006-08-02       Impact factor: 3.918

9.  Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours.

Authors:  C Marian; A Scope; K Laud; E Friedman; F Pavlotsky; E Yakobson; B Bressac-de Paillerets; E Azizi
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

10.  The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.

Authors:  F Lesueur; M de Lichy; M Barrois; G Durand; J Bombled; M-F Avril; A Chompret; F Boitier; G M Lenoir; B Bressac-de Paillerets; Monique Baccard; Bertrand Bachollet; Pascaline Berthet; Valérie Bonadona; Jean-Marie Bonnetblanc; Olivier Caron; Jacqueline Chevrant-Breton; Jean-François Cuny; Stéphane Dalle; Michèle Delaunay; Liliane Demange; Julie De Quatrebarbes; Jean-François Doré; Marc Frénay; Jean-Pierre Fricker; Marion Gauthier-Villars; Paul Gesta; Sophie Giraud; Philippe Gorry; Florent Grange; Andrew Green; Laetitia Huiart; Nicolas Janin; Pascal Joly; Delphine Kérob; Christine Lasset; Dominique Leroux; Jean-Marc Limacher; Michel Longy; Sandrine Mansard; Karine Marrou; Tanguy Martin-Denavit; Christine Mateus; Eve Maubec; Laurence Olivier-Faivre; Vincent Orlandini; Pascal Pujol; Bruno Sassolas; Dominique Stoppa-Lyonnet; Luc Thomas; Pierre Vabres; Laurence Venat; Ewa Wierzbicka; Hélène Zattara
Journal:  Br J Cancer       Date:  2008-07-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.